Please login to the form below

tralokinumab

This page shows the latest tralokinumab news and features for those working in and with pharma, biotech and healthcare.

AZ’s Fasenra hit by COPD trial failure

IL-13 inhibitor tralokinumab has been abandoned after three failed late-stage trials, however, while AZ also has an Amgen-partnered thymic stromal lymphopoietin (TSLP) targeting antibody - tezepelumab - in phase III

Latest news

AZ gets EMA green light for severe asthma drug Fasenra

Prospects for IL-13 inhibitor tralokinumab look terminal after three failed late-stage trials, however, and AZ also has an Amgen-partnered thymic stromal lymphopoietin (TSLP) targeting antibody - tezepelumab - in phase
AZ prices severe asthma drug Fasenra below competition

Prospects for IL-13 inhibitor tralokinumab look rocky after two failed late-stage trials, elevating the importance of Fasenra in those plans.
AZ severe asthma drug benralizumab backed by CHMP

Benralizumab has assumed much greater importance for the company since IL-13 inhibitor tralokinumab - another severe asthma candidate - failed two phase III trials.
Setback for AZ as tralokinumab flunks asthma trial

Setback for AZ as tralokinumab flunks asthma trial. Puts more pressure on AZ’s benralizumab to reach its potential. ... Tralokinumab is an inhibitor of interleukin-13 (IL-13), while benralizumab works by blocking the activity of IL-5.
Roche out-licenses lebrikizumab rights to Dermira

Disappointing results with other IL-13-targeting drugs in asthma - including Pfizer's anrukinzumab and AstraZeneca's tralokinumab - undermined confidence in the approach.

More from news
Approximately 4 fully matching, plus 16 partially matching documents found.

Latest Intelligence

Leo has its eyes on the prize

Its landmark partnership with AstraZeneca and the launch of Kyntheum, the fully-human monoclonal antibody targeting psoriasis, and the phase III hope of tralokinumab for atopic dermatitis are part of an
2016: The year when deal-makers took stock?

Out-partnering deals included the $1.1bn licence to LEO for tralokinumab in skin diseases and the $1bn divestment to Pfizer of its late-stage small molecule anti-infective business.
Deal Watch July 2016

AstraZeneca is developing tralokinumab for severe asthma, where it is in phase III development, and has recently completed a phase IIb study in patients with atopic dermatitis. ... Acquisition. 1, 530. AstraZeneca/ Leo Pharma. Tralokinumab (anti-IL-13)

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Senior Account Manager - Med Comms: Highly Competitive Salary &Benefits

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Account Manager, Healthcare Communications: £32, 000 - £40, 000 benefits

Associate Medical Director: Highly Competitive

Account Director: Negotiable

Senior Account Executive – Medical Communications: Salary TBC

Lead Medical Copywriter, Healthcare Brand Communications, London: Excellent package

Account Director – Global Healthcare PR: Salary TBC

Director – Head of Public Affairs: Neg

Director Healthcare PR Communications: Salary TBC

Editorial Director – Medical Education: Neg

Scientific Team Lead: Competitive Salary

Senior Account Manager / Account Director - Med Comms: Great salary and benefits

Account Director - Digital: Great salary and benefits

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Project / Account Manager (Medical Education): Salary TBC

Experienced Editor, London, Medical Communications: Competitive package

Senior Medical Writer (Remote Working): Competitive Salary Offered

SENIOR MEDICAL WRITER IN ONCOLOGY: Up to £60, 000.00 pension bonus

Account Manager- Manchester, Macclesfield or Glasgow: Negotiable

Associate Medical Director: Salary TBC

Scientific Director: Highly Competitive Salary &Benefits

Medical Strategic Director, Healthcare Advertising Agency: Salary TBC

Account Manager, Healthcare Advertising: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

Retaining reader value in plain language summaries of clinical studies: Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?: Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Making Europe a leader in bioscience: boosting trust and opening minds: A vision of Paris as Europe’s leading hub for life sciences innovation...